In its fourth major biopharma deal since its 2019 founding, Repertoire Immune Medicines signed a partnership with Eli Lilly and Co. to develop tolerizing therapies for several autoimmune diseases, ...
New Scientist on MSN
This virus infects most of us – but why do only some get very ill?
The ubiquitous Epstein-Barr virus is increasingly being linked to conditions like multiple sclerosis and lupus. But why do ...
New data challenge common beliefs about antihistamines, corticosteroids, and vaccines in chronic urticaria, with practical ...
Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America ...
MedPage Today on MSN
Thymectomy in Myasthenia Gravis: Who Benefits?
Decisions may depend on thymoma and what type of auto-antibodies are present ...
A new study published in the journal of Arthritis & Rheumatology showed that occupational inhalants have been linked to ...
While the fabled fountain of youth may not actually exist, a new type of therapy now does.
About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for ...
Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 weeks, according to data published in Arthritis & Rheumatology.“As a ...
A new standard in wheat immune reactivity testing that adds seven new wheat markers to assess immune responses to ...
The study highlights a presymptomatic phase in type 1 diabetes progression, using immune niches to track immune changes ...
Northwestern Medicine scientists in the laboratory of Stephen Miller, Ph.D., professor emeritus of Microbiology–Immunology, have identified the cellular and molecular mechanisms required for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results